Retraction Watch

Tracking retractions as a window into the scientific process

Search Results

Case report of stem cell therapy in child didn’t meet “ethical standards,” says journal

without comments

A journal has retracted a recent case report about a stem cell therapy in a child with cerebral palsy, after discovering the study failed to meet “ethical standards.”

According to the journal, Regenerative Medicine, the ethical issue is that the authors failed to report the case to the Ministry of Health, Labor and Welfare of Japan, which violates the country’s guidelines for conducting stem cell research. Unfortunately, we don’t know much more than that about what happened.

Laura Dormer, editorial director of Future Science Group, which publishes Regenerative Medicine, explained that the paper’s first author, Masato Kantake, requested the retraction because: Read the rest of this entry »

Bone researcher is up to 17 retractions

with 4 comments

A bone researcher has lost three more papers for scientific misconduct.

The new retractions bring Yoshihiro Sato’s total to 17 and put him on our Leaderboard.

According to the retraction notices, Sato asked the Journal of Neurology, Neurosurgery, and Psychiatry to retract three of his papers “due to scientific misconduct.” In the letter, Sato—who is corresponding author on all three papers—explained he included co-authors without their consent and that none of the other authors listed worked on the study or article.

In May, the editors issued expressions of concern while they investigated (1, 2, 3), and last month, the journal retracted the three articles.

Here’s the retraction notice for “Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease:” Read the rest of this entry »

JAMA tells readers: “Caution advised.” Here’s why.

with 8 comments

Last week, JAMA issued some unusual notices, letting readers know they should use caution when reading an editorial and letters associated with now-retracted articles by a bone researcher in Japan.

The notices — for papers by Yoshihiro Sato, now up to 14 retractions — remind readers not to heed the results of the now-retracted papers, and alert them to read any associated materials (specifically, an editorial in JAMA and letters in JAMA Internal Medicine) with caution.

The text of the notices describes them as “formal correction notices;” we asked Annette Flanagin, executive managing editor at The JAMA Network, why they chose that approach, instead of an expression of concern or retraction:

Read the rest of this entry »

Two in 100 clinical trials in eight major journals likely contain inaccurate data: Study

with 2 comments

A sweeping analysis of more than 5,000 papers in eight leading medical journals has found compelling evidence of suspect data in roughly 2% of randomized controlled clinical trials in those journals.

Although the analysis, by John Carlisle, an anesthetist in the United Kingdom, could not determine whether the concerning data were tainted by misconduct or sloppiness, it suggests that editors of the journals have some investigating to do. Of the 98 studies identified by the method, only 16 have already been retracted. [See update at end.]

The types of studies analyzed — randomized controlled clinical trials — are considered the gold standard of medical evidence, and tend to be the basis for drug approvals and changes in clinical practice. Carlisle, according to an editorial by John Loadsman and Tim McCulloch accompanying the new study published today in Anesthesia, Read the rest of this entry »

Written by Ivan Oransky

June 5th, 2017 at 3:45 am

A shadow was cast on a bone researcher’s work. What are journals doing about his papers?

with one comment

Last year, a researcher cast doubt on a bone scientist’s clinical trials, suggesting some of the findings may not be legitimate. So what’s happened since?

Since 2015, journals have retracted 14 papers by bone researcher Yoshihiro Sato, based at Mitate Hospital in Japan, for issues ranging from self-plagiarism, to problems with data, to including co-authors without their consent. (We covered the latest two retractions this week.) Last year’s analysis identified patterns in more than 30 of Sato’s clinical trials that suggest systematic problems with the results. (Sato has defended his research.)

With doubts cast on Sato’s body of work, we contacted the journals that have published his papers involving human trials, to see if any taken another look at Sato’s work; several responded. While most believe there is little reason to take further action at this time, some told us they are investigating.
Read the rest of this entry »

Fraud by bone researcher takes down two meta-analyses, a clinical trial, and review

with 4 comments

The troubles continue for a bone researcher, who’s lost multiple papers in recent months due to problems ranging from data issues to including authors without their consent.

Now, journals have retracted two more papers by Yoshihiro Sato. And in a sign of the downstream effects that fraud can have, another journal has retracted two meta-analyses by other authors that cited his work.

Earlier this month, the journal Current Medical Research and Opinion retracted the two meta-analyses because they were based on recently retracted papers by Sato, affiliated with Mitate Hospital. The two new retractions of Sato’s papers are a review and a randomized controlled trial.

Sato was not an author on the meta-analyses published in 2008 and 2011; he was, however, first and lead author on all the retracted papers referenced in the notices. The notices state that the trio of authors on the meta-analyses:

Read the rest of this entry »

Weekend reads: A publisher sends the wrong message on data sharing; jail for scientific fraud; pigs fly

with 14 comments

The week at Retraction Watch featured three new ways companies are trying to scam authors, and a look at why one journal is publishing a running tally of their retractions. Here’s what was happening elsewhere: Read the rest of this entry »

Written by Ivan Oransky

March 11th, 2017 at 9:31 am

Posted in weekend reads

Author says he lied about approval for animal research

with one comment

A researcher in South Korea has retracted a 2015 paper after telling the journal he falsified the institutional approval required to conduct the animal experiments.

In the article, the author explicitly says that the Animal Experiment Review Board of a university based in Seoul, South Korea approved the experiments, but according to the journal, “the author did not receive an approval by the board and he used a false approval number.”

Here’s the retraction notice for “The role of compensatory movements patterns in spontaneous recovery after stroke,” published in the Journal of Physical Therapy Science (JPTS) in September 2015 and retracted in December: Read the rest of this entry »

Dear Peer Reviewer: Could you also replicate the experiments? Thanks

with 14 comments

via the University of St Andrews

As if peer reviewers weren’t overburdened enough, imagine if journals asked them to also independently replicate the experiments they were reviewing? True, replication is a big problem — and always has been. At the November 2016 SpotOn conference in London, UK historian Noah Moxham of the University of St Andrews in Scotland mentioned that, in the past, some peer reviewers did replicate experiments. We asked him to expand on the phenomenon here.

Retraction Watch: During what periods in history did peer reviewers repeat experiments? And how common was the practice? Read the rest of this entry »

Written by Dalmeet Singh Chawla

January 9th, 2017 at 11:00 am

Japan group earns 4th retraction following investigation

without comments

Researchers in Japan have issued their fourth retraction, noting that the same figures were used to depict different experimental conditions.

The group lost two papers in 2015 for the same reason, following a misconduct investigation at Oita University in Japan. Last year, the same group notched another retraction, and pegged the responsibility for the problematic figures on first author Satoshi Hagiwara.

Now, the group has published a fourth retraction in the European Journal of Pharmacologythe latest notice doesn’t identify a culprit. All four retracted papers list Hagiwara as first author.

Here’s the latest retraction notice: Read the rest of this entry »